Codexis (CDXS) Raised to “Buy” at ValuEngine

ValuEngine upgraded shares of Codexis (NASDAQ:CDXS) from a hold rating to a buy rating in a research note issued to investors on Monday morning.

Several other equities analysts also recently weighed in on the company. Zacks Investment Research downgraded Codexis from a hold rating to a sell rating in a research report on Wednesday, March 14th. HC Wainwright set a $12.00 price target on Codexis and gave the company a buy rating in a report on Monday, March 12th. Finally, BidaskClub raised Codexis from a buy rating to a strong-buy rating in a report on Saturday, March 3rd. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. Codexis presently has a consensus rating of Buy and an average price target of $9.75.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ CDXS traded down $0.40 during midday trading on Monday, hitting $10.30. The stock had a trading volume of 1,606,479 shares, compared to its average volume of 357,033. The company has a market cap of $523.08, a PE ratio of -21.40 and a beta of -1.73. Codexis has a 1 year low of $3.95 and a 1 year high of $13.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.80 and a quick ratio of 1.76.

Codexis (NASDAQ:CDXS) last released its earnings results on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.03). The firm had revenue of $21.70 million during the quarter, compared to analysts’ expectations of $22.97 million. Codexis had a negative net margin of 45.97% and a negative return on equity of 103.42%. The business’s revenue was up 117.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.07) EPS. equities research analysts anticipate that Codexis will post -0.25 EPS for the current fiscal year.

In related news, Director Thomas R. Baruch sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $11.05, for a total value of $276,250.00. Following the completion of the sale, the director now owns 184,670 shares of the company’s stock, valued at $2,040,603.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bernard J. Kelley sold 10,206 shares of the stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $12.22, for a total value of $124,717.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,337 shares of company stock valued at $1,187,683. Insiders own 9.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. MetLife Investment Advisors LLC acquired a new stake in Codexis during the fourth quarter worth $179,000. Two Sigma Investments LP acquired a new stake in Codexis during the fourth quarter worth $518,000. Goldman Sachs Group Inc. increased its stake in Codexis by 57.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 41,931 shares of the biotechnology company’s stock worth $350,000 after acquiring an additional 15,363 shares during the last quarter. Deutsche Bank AG increased its stake in Codexis by 67.0% during the fourth quarter. Deutsche Bank AG now owns 107,089 shares of the biotechnology company’s stock worth $890,000 after acquiring an additional 42,955 shares during the last quarter. Finally, Telemark Asset Management LLC increased its stake in Codexis by 58.5% during the fourth quarter. Telemark Asset Management LLC now owns 3,250,000 shares of the biotechnology company’s stock worth $27,138,000 after acquiring an additional 1,200,000 shares during the last quarter. 70.84% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3335503/codexis-cdxs-raised-to-buy-at-valuengine.html.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Critical Review: Codexis  & FutureFuel
Critical Review: Codexis & FutureFuel
Reviewing iRobot  and SodaStream
Reviewing iRobot and SodaStream
Bitauto Hldg Ltd  Given Consensus Recommendation of “Hold” by Brokerages
Bitauto Hldg Ltd Given Consensus Recommendation of “Hold” by Brokerages
Eldorado Gold Corp  Receives Consensus Recommendation of “Hold” from Brokerages
Eldorado Gold Corp Receives Consensus Recommendation of “Hold” from Brokerages
Analysts Anticipate Sogou  to Announce $0.05 EPS
Analysts Anticipate Sogou to Announce $0.05 EPS
AK Steel  versus Its Peers Head-To-Head Contrast
AK Steel versus Its Peers Head-To-Head Contrast


© 2006-2018 Ticker Report. Google+.